BR112014010009A2 - "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão" - Google Patents

"anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"

Info

Publication number
BR112014010009A2
BR112014010009A2 BR112014010009A BR112014010009A BR112014010009A2 BR 112014010009 A2 BR112014010009 A2 BR 112014010009A2 BR 112014010009 A BR112014010009 A BR 112014010009A BR 112014010009 A BR112014010009 A BR 112014010009A BR 112014010009 A2 BR112014010009 A2 BR 112014010009A2
Authority
BR
Brazil
Prior art keywords
treatment
lymphocytic leukemia
antibody
prevention
nucleic acid
Prior art date
Application number
BR112014010009A
Other languages
English (en)
Inventor
C Wu Cristina
Zhang Suping
J Kipps Thomas
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112014010009A2 publication Critical patent/BR112014010009A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

resumo patente de invenção: "cd44 anticorpo monoclonal para tratamento de leucemia linfocítica crônica de célula-b e de outras malignidades hematológicas". composições, incluindo um anticorpo específico para cd44 são providas. estes anticorpos ligam-se especificamente a células malignas hematológicas. métodos para usar os anticorpos cd44 a células-alvo expressando cd44 para fins terapêuticos e de diagnósticos também são providos. 21118337v1 1/1 21118337v1
BR112014010009A 2011-10-26 2012-10-26 "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão" BR112014010009A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551852P 2011-10-26 2011-10-26
PCT/US2012/062266 WO2013063498A1 (en) 2011-10-26 2012-10-26 Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies

Publications (1)

Publication Number Publication Date
BR112014010009A2 true BR112014010009A2 (pt) 2017-04-25

Family

ID=47143316

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010009A BR112014010009A2 (pt) 2011-10-26 2012-10-26 "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"

Country Status (13)

Country Link
US (1) US20140308301A1 (pt)
EP (1) EP2771363A1 (pt)
JP (1) JP2014534221A (pt)
KR (1) KR20140090997A (pt)
CN (1) CN103946239A (pt)
AU (1) AU2012328512A1 (pt)
BR (1) BR112014010009A2 (pt)
CA (1) CA2851545A1 (pt)
IL (1) IL231902A0 (pt)
MX (1) MX2014004969A (pt)
RU (1) RU2014120577A (pt)
SG (1) SG11201401405PA (pt)
WO (1) WO2013063498A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535452B (zh) 2015-01-23 2016-06-01 長庚醫療財團法人 使用抗－ｃｄ４４中和抗體來治療和／或預防心房顫動
ES2959608T3 (es) * 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
EP4153192A1 (en) 2020-05-19 2023-03-29 Institut Curie Methods for the diagnosis and treatment of cytokine release syndrome
JP2024518200A (ja) 2021-05-18 2024-04-30 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050031610A1 (en) * 2002-07-19 2005-02-10 Tae-Wan Kim CD44-related fragments, compositions and methods
EP1689781A4 (en) * 2003-11-07 2007-06-13 Brigham & Womens Hospital ANTIBODIES TO CD44 GLYCOFORMS AND ITS APPLICATIONS
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
WO2010058396A1 (en) * 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
CN102741292B (zh) * 2010-02-04 2015-10-21 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体

Also Published As

Publication number Publication date
AU2012328512A1 (en) 2014-05-08
KR20140090997A (ko) 2014-07-18
US20140308301A1 (en) 2014-10-16
CN103946239A (zh) 2014-07-23
WO2013063498A1 (en) 2013-05-02
JP2014534221A (ja) 2014-12-18
SG11201401405PA (en) 2014-05-29
IL231902A0 (en) 2014-05-28
RU2014120577A (ru) 2015-12-10
MX2014004969A (es) 2014-05-30
EP2771363A1 (en) 2014-09-03
CA2851545A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
BR112018077362A2 (pt) conjugados para edição de superfície de célula-alvo
BR112014010009A2 (pt) "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112015001839A2 (pt) ibrutinibe deuterado
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
BRPI0606547A2 (pt) anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
EA201590207A1 (ru) Композиции и способы регуляции car-т-клеток
CL2009000379A1 (es) Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
MX2015006374A (es) Anticuerpos anti-ceacam5 y usos de los mismos.
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
MX2011011075A (es) Anticuerpos especificos para cadherina-17.
BR112013009551A2 (pt) anticorpos
WO2012047317A3 (en) Tumor specific antibodies and uses therefor

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]